Wang and colleagues focused on the efficacy of anti-CTLA-4 and anti-PD-1/PD-L1 immunotherapies in NSCLC and found that males had an improved magnitude of clinical benefit from PD-1/PD-L1 therapies but not CLLA4 therapies [61]. Here, CTLA4 is linked to non-small cell lung carcinoma.